Furthermore, activation of p53 signaling with long-term, low-dose doxorubicin treatment reduced liver triglyceride content in diet-induced NAFLD mouse models [39]. This evidence concerns the gene TP53 and metabolic dysfunction-associated steatotic liver disease.